Back A A A Font Size Receive E-mail Alerts Press Releases

Three Subsidiaries of MicroPort® Awarded the Title of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise

[2019-02-25] 

Shanghai, China – The Shanghai Municipal Commission of Economy and Informatization made public the list of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprises on February 12. A total of three subsidiary companies of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), which are Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"), Shanghai MicroPort Endovascular MedTech Co., Ltd. ("MicroPort® Endovascular"), and MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), are included in the list, making the first-time mention for MicroPort® NeuroTech as well as the second time for MicroPort® EP and MicroPort® Endovascular.
 
Guiding the small and medium-size enterprises to become Specialized, Refined, Characteristic and Novel is one of the major measures taken by the Chinese Communist Party Central and the State Council to promote the high-quality development for the small and medium-size enterprises. Since Shanghai launched the Project on the Cultivation of Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprises in 2011, the Shanghai Municipal Commission of Economy and Informatization have been adhering to the Specialized, Refined, Characteristic and Novel approach to discover and cultivate a batch of high-growth enterprises that concentrate on the core business, possess independent intellectual property, own unique processes and techniques, and have competitive advantages.
 
The universal requirements to qualify as a Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise are: the annual revenue in the previous year should amount to no less than 10 million yuan, and the year-over-year revenue growth in the most recent year should not be lower than 15% in principle; or the average year-over-year revenue growth in the past two consecutive years should not be lower than 10% in principle. In addition, there are special requirements: Specialized means that the enterprises should concentrate on their core business and rank among the top 10 in their respective market segments; Refined means that they should have refined production, management or service; Characteristic means that they should have the characteristics of uniqueness and exclusive production; and Novel means that they should have innovation in techniques and management and form the novel competitive advantages.
 
MicroPort® EP was founded in 2010 and is dedicated to the R&D, production, marketing of various kinds of medical devices and equipment that are related to the interventional diagnosis and treatment in cardiac electrophysiology, including ablation catheters, diagnosis catheters, and 3D EP navigation systems. MicroPort® Endovascular was established in 2012 and produces mainly aortic stent-graft systems, stent-graft systems in surgical operation, and big balloons and peripheral vascular stents. MicroPort® NeuroTech was founded in 2012 and is committed to the R&D, manufacturing, marketing, and technical support of the medical devices that treat the central nervous system diseases. The products of the three companies are widely used at Chinese top-tier hospitals and exported to many foreign countries and regions. Previously, they had won the titles of Shanghai Municipality Science and Technology Young Giant Enterprise, Shanghai Municipality High and New-Tech Enterprise, and Shanghai Municipality Patent Work Pilot Enterprise for several times.
 
MicroPort® and its subsidiary companies are always focused on independent innovation and constantly make above industry average investment in research and development. The Shanghai Municipal Government awarded the title of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise to MicroPort® EP, MicroPort® Endovascular and MicroPort® NeuroTech in recognition of MicroPort® and the subsidiary companies’ innovative achievements in the past years. In the future, the MicroPort® companies will continue to take the specialized, refined, characteristic and novel approaches to adhere to independent innovation, enhance core competitiveness, explore domestic and overseas markets, and establish competitive and influential products and brands, so as to build more leading enterprises in various segments of the medical device industry.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:MicroPort® Panoramic Endoscope Design Wins iF DESIGN AWARD 2019
[Next]:MicroPort® Orthopedics Aspiration Medial Stability Total Knee Replacement System – PS Type Implant Obtains Approval in China